Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Genoskin has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 2 examiners and 2 art units, so each follows a separate examination path.
KNIGHT, TERESA E is the busiest examiner, with 1 pending matter. Counsel should use application-specific responses while checking for common biotechnology or pharmaceutical issues across the matters.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KNIGHT, TERESA E | 1 | 66.1% | +48.1% |
| MIANO, JOSEPH PAUL | 1 | 35.7% | +63.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18778233 | EX VIVO MODEL OF INFLAMED HUMAN SKIN AND USES THEREOF FOR SCREENING ANTI-INFLAMMATORY COMPOUNDS | MIANO, JOSEPH PAUL | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18923157 | EX VIVO SUBCUTANEOUS INJECTION MODEL | KNIGHT, TERESA E | — |
| 18778233 | EX VIVO MODEL OF INFLAMED HUMAN SKIN AND USES THEREOF FOR SCREENING ANTI-INFLAMMATORY COMPOUNDS | MIANO, JOSEPH PAUL | — |
| Art Unit | Apps |
|---|---|
| 1634 | 1 |
| 1631 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18923157 | EX VIVO SUBCUTANEOUS INJECTION MODEL | KNIGHT, TERESA E | 1634 | §112DP | Non-Final OA | — | Pending | Oct 22, 2024 |
| 18778233 | EX VIVO MODEL OF INFLAMED HUMAN SKIN AND USES THEREOF FOR SCREENING ANTI-INFLAMMATORY COMPOUNDS | MIANO, JOSEPH PAUL | 1631 | §101§112DP | Non-Final OA | — | Pending | Jul 19, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGenoskin has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Teresa E Knight has the most, with 1 of Genoskin's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
